Success Metrics

Clinical Success Rate
50.0%

Based on 2 completed trials

Completion Rate
50%(2/4)
Active Trials
0(0%)
Results Posted
150%(3 trials)
Terminated
2(50%)

Phase Distribution

Ph not_applicable
1
25%
Ph phase_1
1
25%

Phase Distribution

1

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
N/ANon-phased studies
1(50.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(2)
Terminated(2)

Detailed Status

Completed2
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
50.0%
Most Advanced
Phase 1

Trials by Phase

Phase 11 (50.0%)
N/A1 (50.0%)

Trials by Status

completed250%
terminated250%

Recent Activity

0 active trials
Showing 4 of 4
completed

Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System

NCT02392078
completed

PatiEnt Neuropsychological outcomeS After laseR Ablation

NCT05075850
terminatednot_applicable

Feasibility Study on LITT for Medical Refractory Epilepsy

NCT02820740
terminatedphase_1

Feasibility Study on LITT for Newly Diagnosed Glioblastoma

NCT02880410

Clinical Trials (4)

Showing 4 of 4 trials
NCT02392078

Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System

Completed
NCT05075850

PatiEnt Neuropsychological outcomeS After laseR Ablation

Completed
NCT02820740Not Applicable

Feasibility Study on LITT for Medical Refractory Epilepsy

Terminated
NCT02880410Phase 1

Feasibility Study on LITT for Newly Diagnosed Glioblastoma

Terminated

All 4 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
4